Nautilus Biotechnology, Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. Its core offering, the Nautilus Platform, provides an end-to-end proteomics solution that includes instruments, consumables, and software for analysis, enabling high-resolution optical imaging, fluidics, and liquid handling to process protein libraries and decode proteins in biological samples. The company has developed the Voyager Platform, a benchtop system supporting Iterative Mapping to analyze up to 10 billion intact proteins and proteoforms in a single run, along with specialized assays like tau proteoforms for neurodegenerative disease research and alpha-synuclein for Parkinson's biomarkers. Nautilus Biotechnology, Inc. runs an Early Access Program granting select researchers exclusive access, data interpretation support, and custom assay development, fostering collaborations with institutions such as Weill Cornell Medicine-Qatar and the Michael J. Fox Foundation. Headquartered in Seattle, Washington, and founded in 2016, the company advances proteomics to support breakthroughs in human health and medicine, particularly in Alzheimer's and other neurodegenerative areas.